FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Opioid Disorder Effectiveness Endpoint Guidance

FDA issues a guidance on clinical endpoints to demonstrate the effectiveness of drugs indicated to treat opioid use disorder.

Human Drugs

Guidances on Adjuvant Treatments for Renal, Bladder Cancer

FDA publishes guidances on developing drugs and biologics for adjuvant treatment of two types of cancer.

Federal Register

Guide on Using Physiologically Based Pharmacokinetic Analyses

Federal Register notice: FDA makes available a draft guidance entitled The Use of Physiologically Based Pharmacokinetic Analyses Biopharmaceutics App...

Federal Register

Draft Guide on QT Prolongation Evaluation Q&As

Federal Register notice: FDA makes available a draft guidance entitled E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation...

Human Drugs

AndroGel Case Remanded to Pennsylvania Federal Court

The 3rd Circuit Court of Appeals says a Pennsylvania federal court erred in portions of its decision in a case involving AndroGel marketing brought by...

Human Drugs

Drug Company Profits Push Prices: Reports

Two House Oversight Committee reports say excessive drug company profits are the primary driver of higher prescription drug prices.

Court Questions Criminalizing Off-Label Promotion

Attorney Stephen McConnell says the Massachusetts federal court is calling for Congress and FDA to reconsider the statutory and regulatory basis for p...

Human Drugs

Clinical Hold on Gene Therapy Lifted

FDA lifts a clinical hold against Solid Biosciences IGNITE DMD Phase 1/2 clinical trial involving SGT-001, a novel adeno-associated viral vector-media...

Human Drugs

FDA Clinical Trial Oversight Slipping: Report

A review of FDA inspection documents by the journal Science on the agencys clinical trial oversight during the past 11 years shows enforcement is ofte...

FDA General

Political Intrusion Prolongs the Pandemic: Op-Ed

Seven former FDA commissioners call on the White House to let FDA do its scientific work without political interference.